Possible prognostic impact of WT1 mRNA expression at day + 30 after haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide for patients with myeloid neoplasm: a multicenter study from the Okayama Hematological Study Group

Kitamura, Wataru; Fujii, Nobuharu; Nawa, Yuichiro; Fujishita, Keigo; Sugiura, Hiroyuki; Yoshioka, Tomoko; Fujiwara, Yuki; Usui, Yoshiaki; Fujii, Keiko; Fujiwara, Hideaki; Asada, Noboru; Nishimori, Hisakazu; Matsuoka, Ken‐ichi; Maeda, Yoshinobu

doi:10.1007/s12185-022-03290-3

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite1

Independent0

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Certainly, multiparametric flow cytometry was recommended to evaluate measurable residual disease [ 10 ], but multiparametric flow cytometry was not approved in Japan and we could not perform it to evaluate disease status. In addition, WT1 mRNA levels of less than 50 copies/μg RNA on day 30 after transplant were reported as a possible positive prognostic factor for PTCy-haplo-PBSCT [ 11 ] and may also be useful for the assessment of disease status after transplantation in VEN+AZA bridging PTCy-haplo-PBSCT.…”

Section: Discussionmentioning

confidence: 99%

Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with IDH2 Mutations

Daido,

Sugiura,

Ishikawa

et al. 2023

Case Rep Oncol

Self Cite

View full text Add to dashboard Cite

Venetoclax and azacitidine combination therapy (VEN+AZA) is a promising novel therapy for elderly or unfit patients with acute myeloid leukemia (AML). Recently, VEN+AZA with subsequent allo-hematopoietic stem cell transplantation has been reported, and human leukocyte antigen-haploidentical peripheral blood stem cell transplantation using posttransplant cyclophosphamide (PTCy-haplo-PBSCT) from related donors appears to be a suitable option. Here, we report two elderly patients with refractory AML harboring an IDH2 mutation, who were successfully treated with VEN+AZA bridged to PTCy-haplo-PBSCT. This report suggests the efficacy and safety of VEN+AZA as a bridging treatment for PTCy-haplo-PBSCT in refractory AML.

show abstract

Section: Discussionmentioning

confidence: 99%